ALLOZYNE INC について
Allozyne was a clinical stage biotechnology company headquartered in Seattle's biotech and high tech innovation corridor. Allozyne was founded in 2005 by California Institute of Technology researchers, and was incubated by Accelerator Corporation. Its lead product candidate, AZ01, is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic degenerative disease characterized by demyelination of nerve fibers leading to severe nerve damage and increasing disability. Multiple sclerosis is estimated to affect 400,000 individuals in the US alone and 2.5 million worldwide. AZ01 is currently undergoing Phase I clinical trials in the US. Preclinical data indicates that AZ01 has the potential to be dosed once monthly compared to the current standard of care dosed anywhere from once daily to once per week.
Source: Wikipedia
業界Biotechnology
本部Seattle, WA
設立2005
法人形態C Corporation
状態アクティブ
主要データ
ログインして主要な数値を見る
ALLOZYNE INCの売上高、純利益、従業員数の推移(出典付き)。
サインイン メールアドレスでアカウントを作成無料です
続行すると、Heelkyのユーザー契約、プライバシーポリシー、Cookieポリシーに同意したものとみなされます。
法的情報
| 正式名称 | ALLOZYNE INC |
|---|---|
| 法人形態 | C Corporation |
| SEC CIK | 1345630SEC EDGAR で見る ↗ |
| 登記住所 | Seattle, WA |
| 状態 | アクティブ |
出典: SEC EDGAR · 2026年11月14日 に更新